

February 1, 2016

The Surveillance & Supervision Department
BSE LIMITED
25th Floor, Dalal Street,
PJ Towers,
MUMBAI-400 001

Dear Sirs,

Sub: Clarification on News Item

Ref: 1) Your letter No.L/DOSS/ONL/RV/JP/2015-16/215 dated February 1, 2016
2) Our Company Code No. 524804.

We refer to your letter dated 01.02.2016, with regard to the news item which appeared in www.Moneycontrol.com on the USFDA inspection in Unit III and Unit VII of the Company. This is to clarify that the said facilities underwent pre-approval inspection by USFDA and there was no Form 483 issued for Unit III. With regards to Unit VII, there were certain observations. The Company is appropriately responding and this has no perceived impact on the operations and exports from the said facility.

Please take the information on record.

Thanking you,

Yours faithfully,
For **AUROBINDO PHARMA LIMITED**


A.MOHAN RAMI REDDY
Vice President (Legal) & Company Secretary



AUROBINDO PHARMA LIMITED

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad - 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059
Regd. Off. : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

www.aurobindo.com